- Home
- CBU vs ZLAB Comparison
CBU vs ZLAB Comparison
Compare CBU & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBU
- ZLAB
- Stock Information
- Founded
- CBU 1866
- ZLAB 2013
- Country
- CBU United States
- ZLAB China
- Employees
- CBU N/A
- ZLAB N/A
- Industry
- CBU Major Banks
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- CBU Finance
- ZLAB Health Care
- Exchange
- CBU Nasdaq
- ZLAB Nasdaq
- Market Cap
- CBU 3.0B
- ZLAB 3.0B
- IPO Year
- CBU N/A
- ZLAB 2017
- Fundamental
- Price
- CBU $68.59
- ZLAB $27.38
- Analyst Decision
- CBU Buy
- ZLAB Strong Buy
- Analyst Count
- CBU 3
- ZLAB 4
- Target Price
- CBU $58.67
- ZLAB $52.50
- AVG Volume (30 Days)
- CBU 300.4K
- ZLAB 1.2M
- Earning Date
- CBU 10-22-2024
- ZLAB 11-12-2024
- Dividend Yield
- CBU 2.66%
- ZLAB N/A
- EPS Growth
- CBU 12.13
- ZLAB N/A
- EPS
- CBU 3.13
- ZLAB N/A
- Revenue
- CBU $706,337,000.00
- ZLAB $355,748,000.00
- Revenue This Year
- CBU N/A
- ZLAB $48.50
- Revenue Next Year
- CBU $8.25
- ZLAB $47.37
- P/E Ratio
- CBU $22.08
- ZLAB N/A
- Revenue Growth
- CBU 10.20
- ZLAB 35.01
- 52 Week Low
- CBU $41.50
- ZLAB $13.48
- 52 Week High
- CBU $72.30
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- CBU 64.53
- ZLAB 49.37
- Support Level
- CBU $68.11
- ZLAB $26.47
- Resistance Level
- CBU $72.30
- ZLAB $32.15
- Average True Range (ATR)
- CBU 2.04
- ZLAB 1.36
- MACD
- CBU 0.56
- ZLAB -0.64
- Stochastic Oscillator
- CBU 78.45
- ZLAB 30.81
About CBU Community Bank System Inc.
Community Financial System Inc is a diversified financial services company that is focused on four main business lines - banking, benefits administration, insurance services and wealth management. The Company also offers comprehensive financial planning, trust administration and wealth management services through its Community Bank Wealth Management operating unit. Key revenue is generated from banking business.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.